Key result
Systemic lupus erythematosus and systemic sclerosis are linked to higher COMPASS-31 scores versus controls.
Why the study?
Autonomic dysfunction may arise in chronic systemic diseases, prompting this study to quantify autonomic symptom burden and clinical correlates in SLE and SSc compared with controls.
Do patients with systemic lupus erythematosus and systemic sclerosis have higher autonomic symptom burden compared to controls?
Cross-Sectional (n=135)
Do patients with systemic lupus erythematosus and systemic sclerosis have higher autonomic symptom burden compared to controls?
Patients with systemic lupus erythematosus and systemic sclerosis have a significantly higher burden of autonomic symptoms compared to controls, which correlates with specific organ involvement.
Answers are grounded in this paper and cite their sources.
Elevated autonomic symptom scores in SLE/SSc may prompt clinical screening; leaves open causal mechanisms and outcome impact.
Background and Objective Autonomic dysfunction may arise in chronic systemic diseases, including autoimmune connective tissue disorders. This study aimed to quantify autonomic symptom burden in patients with systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), examine clinical correlates, and compare results with controls without autoimmune disease. Methods This cross-sectional study included 50 SLE patients, 50 SSc patients, and 35 controls. Clinical and demographic characteristics were collected during visits. Autonomic symptom burden was assessed using the Composite Autonomic Symptom Score-31 (COMPASS-31). COMPASS-31 total and subdomain scores were examined across groups and within disease groups according to clinical and serological variables. A post-hoc COMPASS-31 score >32.5 was used to define high autonomic symptom burden. Results Median total COMPASS-31 scores differed across groups and were higher in both SLE and SSc than in controls (15.43 and 20.53 vs 9.03; p = 0.001). Compared with SLE, SSc had higher orthostatic and vasomotor symptom burden. Using COMPASS-31 > 32.5, high autonomic symptom burden was present in 7/50 (14%) SLE and 13/50 (26%) SSc patients, while none of the controls exceeded the cut-off. In multivariable models, serositis and joint involvement predicted high symptom burden in SLE, whereas clinically significant gastrointestinal involvement and musculoskeletal involvement were independent predictors in SSc. After adjustment for age, sex, and comorbidity, total COMPASS-31 remained higher than in controls in both SLE (β = 7.01; p = 0.013) and SSc (β = 11.24; p < 0.001). Conclusion Autonomic symptom burden appears to be higher in patients with SLE and SSc than in controls. The subgroup differences suggest that autonomic symptoms may cluster with specific organ involvement. COMPASS-31 may be a practical screening tool to identify patients who could benefit from further objective autonomic evaluation. Routine, structured assessment may support timely recognition and management of autonomic symptoms in clinical practice.
No takes yet. Share an insight, caveat, or question.
Avcu et al. (2026) conducted a cross-sectional in Systemic lupus erythematosus and systemic sclerosis (n=135). Systemic lupus erythematosus and systemic sclerosis vs. Controls without autoimmune disease was evaluated on Composite Autonomic Symptom Score-31 (COMPASS-31) total score (p=0.001). Systemic lupus erythematosus and systemic sclerosis were associated with higher median COMPASS-31 scores compared to controls (15.43 and 20.53 vs 9.03; p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: